INTRODUCTION
============

Antibiotic resistance in gram-negative bacteria is a major problem worldwide. Resistance to β-lactam antibiotics is often mediated by β-lactamases, including expanded-spectrum β-lactamases (ESBLs), plasmid-mediated AmpC β-lactamases, and carbapenemases \[[@B1]\]. Clinical isolates of *Klebsiella pneumoniae* are notorious for harboring a wide range of β-lactamases and are naturally resistant to ampicillin and amoxycillin. β-Lactam antibiotics are often used in the treatment of infections caused by this bacterium \[[@B2]\]. The emergence and rapid spread of drug-resistant *K. pneumoniae* isolates has become a serious clinical challenge.

β-Lactamases are grouped into four classes according to their amino acid sequence: class A, including KPC and TEM; class B, the metallo-β-lactamases (MBLs) such as VIM, IMP, and NDM-1; class C, the AmpC β-lactamases; and class D, the oxacillinase (OXA)-type enzymes. All four classes of β-lactamases have been described in *K. pneumoniae*. Carbapenem resistance in *K. pneumoniae* has been reported in most countries and can be attributed to plasmid-mediated AmpC cephalosporinases associated with porin modifications \[[@B3][@B4]\], reduced outer membrane permeability by porin loss in combination with the production of an ESBL, or production of β-lactamases capable of hydrolyzing carbapenems (carbapenemases) \[[@B5][@B6]\]. In Turkey, OXA-48 carbapenemases have been identified for a decade \[[@B5]\], initially described in *K. pneumoniae* \[[@B7]\] and then in various other enterobacterial species \[[@B8][@B9][@B10]\]. Only recently, however, an imported case of NDM-1-producing *K. pneumoniae* has been reported in Turkey \[[@B11]\], but thus far, there have been no reports on locally acquired cases.

In this study, we aimed to characterize the β-lactamases in carbapenem-resistant *K. pneumoniae* clinical isolates from Turkey. These data serve an important role in understanding and controlling the spread of carbapenem-resistant gram-negative pathogens \[[@B2]\].

METHODS
=======

1. Bacterial strains and antibiotic susceptibilities
----------------------------------------------------

The study was performed at the Bezmialem Vakif University Hospital in Turkey between July 2012 and March 2013. During the study period, all non-duplicate clinical isolates of *K. pneumoniae* obtained from inpatients that exhibited a reduced sensitivity to carbapenems were characterized. Clinical isolates were identified by using standard microbiological procedures and VITEK-2 (bioMerieux, Marcy-l\'Etoile, France). The identification of all isolates was confirmed by 16S rDNA sequencing \[[@B12]\]. Susceptibility testing was performed by using the following antibiotics: ampicillin, ampicillin/sulbactam, piperacillin, piperacillin/tazobactam, cefuroxime, ceftazidime, cefoperazone/sulbactam, cefepime, amikacin, gentamicin, netilmicin, tobramycin, ciprofloxacin, levofloxacin, tetracycline, trimethoprim/sulfamethoxazole, imipenem, meropenem, colistin, and tigecycline. Non-susceptibility to carbapenems (imipenem and meropenem) and colistin during susceptibility testing was confirmed by E-test (bioMerieux) in accordance with the CLSI guidelines \[[@B13]\].

2. Detection of β-lactamase genes
---------------------------------

*K. pneumoniae* strains were screened for β-lactamase-encoding genes by PCR. The primers used to amplify the *bla*~SHV~, *bla*~TEM~, *bla*~CTX-M1~, *bla*~CTX-M2~, *bla*~GES~, *bla*~VEB~, *bla*~PER-2~, *bla*~NDM-1~, *bla*~IMP-like~, *bla*~VIM-like~, *bla*~KPC~ and *bla*~OXA-48~ genes are listed in [Table 1](#T1){ref-type="table"}. A single reaction mixture contained 5 µL genomic DNA, 20 pM of each primer, 10 µL reaction buffer, 3 µL 25 mM MgCl~2~, 200 µM dNTPs, and 1.5 U Go *Taq* Flexi Polymerase (Promega, Madison, WI, USA), in a final volume of 50 µL. PCR amplification was performed by using standard conditions with varying annealing temperatures ([Table 1](#T1){ref-type="table"}). All PCR results were analyzed on 1% agarose containing 0.5 µg/mL ethidium bromide and subsequently visualized under UV light. The PCR products for NDM, OXA-48, and TEM β-lactamases were cloned into the pGEM-T Easy vector (Promega) and then sequenced by Macrogen (Amsterdam, The Netherlands). Sequencing results were analyzed by using the alignment search tool, BLAST (<http://www.ncbi.nlm.nih.gov/BLAST>) \[[@B14]\], and the multiple sequence aligment program CLUSTALW2 (<http://www.ebi.ac.uk/Tools/msa/clustalw2/>). The remaining genes were evaluated according to their molecular size and PCR results of control groups which were defined as β-lactamase gene carrier bacteria in the earlier studies \[[@B7][@B15][@B16]\].

3. Repetitive Extragenic Palindronic (REP)-PCR analysis
-------------------------------------------------------

REP-PCR was used in the genotyping of *K. pneumoniae* isolates. The primer pair REP 1 (5\'-IIIGCGCCGICATCAGGC-3\') and REP 2 (5\'-ACGTCTTATCAGGCCTAC-3\') was used \[[@B17]\], and the amplification reaction was performed as previously described \[[@B15]\]. The amplified DNA fragments were separated by electrophoresis on a 1.5% agarose gel with a 1-kb DNA ladder (Sigma Chemicals, Ontario, Canada) as the size marker. The amplified DNA bands were visualized under UV light following ethidium bromide staining, and the banding patterns of each strain were captured by using an UVP bioimaging system (UVP, Upland, CA, USA). The REP-PCR fingerprints were analyzed by using the Phoretix gel analysis package (Nonlinear USA, Inc., Durham, NC, USA).

RESULTS
=======

A total of 37 *K. pneumoniae* isolates were identified during the study period and investigated. All isolates were from hospital-acquired infections, with the majority from patients in the intensive care unit (n=23), followed by patients on surgical (n=7) and medical wards (n=7). Of the 37 isolates, 16 (43%) were associated with bloodstream infections. The remaining isolates came from wounds (n=7, 19%), sputum (n=6, 16%), tracheal aspirates (n=6, 16%), cerebrospinal fluid (n=1, 3%), and a catheter sample (n=1, from anesthesia unit).

According to the antibiotic susceptibility profiles, all 37 isolates were resistant to ampicillin, ampicillin/sulbactam, piperacillin, piperacillin/tazobactam, ceftazidime, cefoperazone/sulbactam, cefepime, imipenem, and meropenem. The lowest levels of resistance were observed for colistin (2.7%) and tigecycline (11%), followed by amikacin (19%) and trimethoprim/sulphamethoxazole (21.6%). Of the 37 *K. pneumoniae* isolates, 98% carried a carbapenemase gene. More specifically, we detected OXA-48 in 32 isolates (86%) and NDM-1 in seven isolates (19%). No other carbapenemases were identified within this group. We also observed a high prevalence of ESBLs, with all strains carrying a CTX-M-2 group β-lactamase and 23 isolates (62%) carrying CTX-M-1. SHV-1-like and TEM-1-like β-lactamase were also common (97% and 92% of strains, respectively). One of the *bla*~TEM~ genes was identified as *bla*~TEM-166~, a variant of *bla*~TEM-1b~ that has one amino acid change at position 53 (Arg53Gly).

The combination of β-lactamases relative to the site of isolation and susceptibility test results are shown in [Table 2](#T2){ref-type="table"}. Importantly, all NDM-1-producing strains were isolated from blood. Furthermore, all blood isolates carried at least one carbapenemase (OXA-48 or NDM-1), and two (13%) carried both OXA-48 and NDM-1. The most common combination of β-lactamases in a given strain was OXA-48, SHV-1-like, TEM-1-like and CTX-M-type β-lactamase, with 76% of strains observed with this combination.

All 37 *K. pneumoniae* strains were typed by REP-PCR ([Fig. 1](#F1){ref-type="fig"}). We observed seven predominant genotypes; the majority of strains (46%) clustered into genotype 6, while 19% and 16% of the isolates clustered in genotype 3 and 1, respectively. Of the 17 genotype 6 isolates, 11 were isolated from the anesthesia and reanimation intensive care unit (ICU), and three were isolated from the thoracic surgery unit. Of the seven genotype 3 isolates, two were isolated from patients who were in the neurology ward at the same time, and two were isolated from the anesthesia and ICU. The remaining isolates were distributed among other wards in the hospital over different times during the 9-month study period ([Table 2](#T2){ref-type="table"}).

DISCUSSION
==========

*K. pneumoniae* is an opportunistic pathogen that causes community- and hospital-acquired infections, such as bloodstream and urinary tract infections, and pneumonia \[[@B18]\]. Currently, carbapenems are the most potent antimicrobial agents used in the treatment of serious infections caused by multidrug-resistant gram-negative bacteria. However, carbapenem resistance in *Enterobacteriaceae* is emerging in Turkey \[[@B8][@B9]\] and in other parts of the world \[[@B5]\]. Here, we described the distribution of major β-lactamases in a contemporary group of extensively drug-resistant *K. pneumoniae* isolates from Turkey. We observed that 19% of isolates carried the NDM-1 carbapenemase, and that all of these isolates came from bloodstream infections and from patients with no recent travel history, suggesting local acquisition. OXA-48 carbapenemases were highly prevalent, and were occasionally found co-existing with NDM-1. Compounding these data was that over 2.7% of isolates were resistant to colistin, a finding that is novel for Turkey and one with serious therapeutic implications. The majority of isolates came from patients in the ICU.

BLs have been reported worldwide, and their genes are often located on plasmids and integrons \[[@B19]\]. NDM is a novel MBL enzyme, and its variants are the latest carbapenemases to be recognized and reported worldwide. NDM-1 was first identified in a carbapenem-resistant *K. pneumoniae* strain from the urine sample of a Swedish patient of Indian origin who traveled to New Delhi \[[@B20]\]. Since then, more than 40 countries have reported NDM-producing isolates \[[@B21][@B22]\]. NDM enzymes have predominately been identified in *Enterobacteriaceae*, but have also been described in non-fermenters and in members of the *Vibrionaceae* family \[[@B23]\].

Occasional community-acquired NDM-1-positive isolates have been reported \[[@B24]\], however, the overwhelming majority of isolates have a nosocomial origin. In our study, all isolates were from nosocomial infections and all were from seriously ill patients. All of the NDM-1-positive isolates (n=7) were recovered from blood samples, and six of these were from patients in the ICU. All patients were uninfected at admission, and the organisms were isolated from patients 48 hr or longer after admission.

In Turkey, NDM-1 was first reported in 2011 in a *K. pneumoniae* isolate from a leukemia patient originally from Iraq \[[@B19]\]. Later, another team investigated NDM-1 in various carbapenemase-resistant gram-negative bacilli, but with negative results \[[@B25]\]. To our knowledge, the current study is the largest report demonstrating the presence of NDM-1 in *K. pneumoniae* in Turkey. Our results indicate that seven out of 37 (19%) carbapenem-resistant *K. pneumonia* isolates were positive for NDM-1, an alarming result as efforts to identify NDM-1-producing isolates in 2011 showed negative results.

Another β-lactamase type known as OXA-48 was initially identified in Turkey from a *K. pneumoniae* isolate from Istanbul, and thereafter, outbreaks of OXA-48-producing *K. pneumoniae* have been described in Turkey \[[@B8][@B9][@B10]\]. To date, 11 variants of OXA-48 have been described \[[@B26]\]. Recently, the molecular characterization of carbapenem-resistant *K. pneumoniae* in a tertiary university hospital in Turkey was performed on 94 isolates. OXA-48 and NDM-1 were produced in 91.5% and 4.3% of isolates, respectively \[[@B27]\]. In our study, OXA-48 and NDM-1 were observed in 86% and 19% of isolates, respectively. This study reveals that the NDM-1 resistance gene is increasing in prevalence in Turkey. This increase poses a significant threat to Turkish infection control efforts.

TEM or SHV β-lactamase derivatives have been the most prevalent ESBLs in nosocomial pathogens since the 1980s. However, starting from 1995, CTX-M-type ESBLs have emerged worldwide, including Europe, Asia, South America, and Canada \[[@B13][@B28]\]. We demonstrated that these CTX-M-type ESBLs are also highly prevalent in multidrug-resistant *K. pneumoniae* in Turkey. In a multicenter study conducted in Turkish hospitals, PCR analysis was used for ESBL typing, and CTX-M was the most prevalent enzyme type among blood isolates (71%) of *Escherichia coli* and *K. pneumonia*, followed by TEM (49%) and SHV (47%) type enzymes \[[@B29]\].

The CTX-M family can be classified into five major groups: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25. CTX-M-15, which belongs to the CTX-M-1 group, is the most widespread of these enzymes around the world \[[@B30]\]. Ours is the first report of CTX-M-1 and CTX-M-2 in ESBL-producing carbapenem-resistant *K. pneumoniae* strains from Turkey. CTX-M-2 was the most prevalent β-lactamase, found in 100% of isolates, followed by SHV (97%), TEM (92%), and CTX-M-1 (62%). The continued monitoring of antimicrobial resistance to β-lactams in each region of Turkey is urgently required to assist with the development of control strategies for hospital infections.

In conclusion, our study of carbapenem-resistant, *K. pneumoniae* isolates identified the largest number of NDM-1-producing strains reported from Turkey, and revealed that these strains were highly resistant to a range of clinically important antibiotics. Furthermore, these isolates often carried the OXA-48 carbapenemase, and were associated with serious infections of the bloodstream. All strains also carried multiple ESBLs, with *bla*~CTX-M-2~ being the most common. The recent emergence of NDM-1-producing *K. pneumoniae* on the background of the highly prevalent OXA-48 and CTX-M type ESBLs is alarming for our country.
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![Repetitive extragenic palindronic (REP)-PCR profiles of 37 *Klebsiella pneumoniae* isolates. Seven different genotypes were observed, and most isolates clustered into genotypes 1, 3, and 6.](alm-35-595-g001){#F1}

###### Primers used for amplication and sequencing in this study
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  Primer                       5\'-3\' Sequence           Amplicon size (bp)   Tm (℃)   Reference
  ---------------------------- -------------------------- -------------------- -------- ------------
  GES                          F: ATGCGCTTCATTCACGCAC     863                  56       \[[@B15]\]
  R: CTATTTGTCCGTGCTCAGGA                                                               
  VEB                          F: ATTTCCCGATGCAAAGCGT     542                  55       
  R: TTATTCCGGAAGTCCCTGT                                                                
  PER-2                        F: ATGAATGTCATCACAAAATG    927                  50       
  R: TCAATCCGGACTCACT                                                                   
  IMP                          F: CATGGTTTGGTGGTTCTTGT    488                  56       
  R: ATAATTTGGCGGACTTTGGC                                                               
  VIM                          F: ATTGGTCTATTTGACCGCGTC   780                  58       
  R: TGCTACTCAACGACTGAGCG                                                               
  NDM                          F: TGGAATTGCCCAATATTATGC   813                  54       
  R: TCAGCGCAGCTTGTCGGCCATGC                                                            
  CTX-M-1 group                F: GCGTGATACCACTTCACCTC    260                  50       \[[@B16]\]
  R: TGAAGTAAGTGACCAGAATC                                                               
  CTX-M-2 group                F: TGATACCACCACGCCGCTC     341                  50       
  R: TATTGCATCAGAAACCGTGGG                                                              
  TEM                          F: AGTATTCAACATTTYCGTGT    860                  49       
  R: TAATCAGTGAGGCACCTATCTC                                                             
  SHV                          F: ATGCGTTATATTCGCCTGTG    843                  55       
  R: TTAGCGTTGCCAGTGCTC                                                                 
  OXA-48                       A: TTGGTGGCATCGATTATCGG    743                  57       \[[@B7]\]
  B: GAGCACTTCTTTTGTGATGGC                                                              
  KPC                          A: CGTTCTTGTCTCTCATGGCC    796                  52       
  B: CCTCGCTGTGCTTGTCATCC                                                               

###### Epidemiological properties of β-lactamase-producing *Klebsiella pneumoniae* isolates
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  Isolate   Specimen            Units   Dates       Treatment                Outcome   Susceptible antibiotics            *bla*~NDM-1~   *bla*~OXA-48~   *bla*~CTX-M1~   *bla*~CTX-M2~   *bla*~TEM~   *bla*~SHV~
  --------- ------------------- ------- ----------- ------------------------ --------- ---------------------------------- -------------- --------------- --------------- --------------- ------------ ------------
  1         Blood               AR      Feb. 2013   SCF, CIP, TIG            Exitus    AK, TIG, CST, SXT                  \-             \-              \+              \+              \+           \+
  2         Blood               Gas     Feb. 2013   NT                       Exitus    AK, CN, TIG, CST, SXT              \-             \+              \+              \+              \-           \+
  3         Blood               Neu     Feb. 2013   TZP, SXT                 Other     CN, TIG, CST, SXT                  \+             \+              \+              \+              \+           \+
  4         Blood               Neu     Feb. 2013   SXT, SCF                 Other     TIG, CST, SXT                      \+             \-              \+              \+              \+           \+
  5         Blood               TS      Jan. 2013   NT                       Other     AK, TIG, CST                       \-             \+              \+              \+              \+           \+
  6         Sputum              TS      Jan. 2013   NT                       Other     AK, CST                            \-             \+              \+              \+              \+           \+
  7         Wound               RO      Jan. 2013   NT                       Other     AK, CN, TIG, CST, SXT              \-             \+              \+              \+              \-           \+
  8         Sputum              TS      Jan. 2013   NT                       Other     AK, TIG, CST, SXT                  \-             \+              \+              \+              \+           \+
  9         Blood               IM      Jan. 2013   SCF, TIG                 Other     AK, TIG, CST, SXT                  \-             \+              \+              \+              \+           \+
  10        Sputum              RICU    Jan. 2013   NT                       Other     AK, CN, NET, TOB, TIG, CST, SXT    \-             \+              \-              \+              \+           \+
  11        Sputum              RICU    Jan. 2013   SCF, TIG                 Exitus    AK, CN, NET, TOB, TIG, CST, SXT    \-             \+              \-              \+              \+           \+
  12        Wound               TS      Jan. 2013   CST, TIG                 Other     AK, CST                            \-             \+              \+              \+              \+           \+
  13        Blood               PS      Jan. 2013   NT                       Other     TIG, CST                           \+             \+              \+              \+              \+           \+
  14        Blood               AR      Jan. 2013   SCF, CST                 Exitus    AK, CN, NET, TOB, TIG, CST, SXT    \+             \-              \+              \+              \+           \+
  15        Tracheal aspirate   AR      Dec. 2012   SCF, TIG                 Exitus    AK, TIG, CST, SXT                  \-             \+              \+              \+              \+           \+
  16        Blood               AR      Dec. 2012   TIG, SXT, CST            Exitus    AK, TIG, CST, SXT                  \-             \+              \+              \+              \+           \+
  17        Blood               Uro     Dec. 2012   NT                       Other     AK, CN, TIG, CST, SXT              \+             \-              \+              \+              \+           \+
  18        Wound               GS      Dec. 2012   MEM, TIG                 Other     AK, CIP, LEV, TET, TIG, CST, SXT   \-             \+              \+              \+              \-           \+
  19        Tracheal aspirate   AR      Dec. 2012   TIG, SUL                 Treated   CN, TIG, CST, SXT                  \-             \+              \+              \+              \+           \+
  20        Blood               AR      Dec. 2012   CST, TIG                 Exitus    AK, TIG, CST, SXT                  \-             \+              \+              \+              \+           \+
  21        Catheter            AR      Dec. 2012   TIG, CST                 Exitus    AK, TIG, CST, SXT                  \-             \+              \+              \+              \+           \+
  22        CSF                 AR      Nov. 2012   SXT, MEM, CIP            Exitus    AK, TIG, CST, SXT                  \-             \+              \+              \+              \+           \+
  23        Sputum              RICU    Feb. 2013   SCF, TIG                 Exitus    AK, CN, TIG, CST, SXT              \-             \+              \-              \+              \+           \+
  24        Blood               RICU    Oct. 2012   TIG, SUL                 Exitus    TIG, SXT                           \-             \+              \-              \+              \+           \+
  25        Blood               AR      Oct. 2012   TIG, SUL                 Exitus    TIG, CST, SXT                      \+             \-              \-              \+              \+           \+
  26        Wound               Gas     Nov. 2012   NT                       Other     AK, TET, TIG, CST, SXT             \-             \+              \-              \+              \+           \-
  27        Wound               AR      Jul. 2012   MEM, CIP, TIG, AK        Other     CN, CST                            \-             \+              \+              \+              \+           \+
  28        Blood               AR      Oct. 2012   SCF, CIP                 Other     AK, TIG, CST, SXT                  \-             \+              \-              \+              \+           \+
  29        Wound               AR      Oct. 2012   CST, SUL, TIG, AK        Exitus    AK, TIG, CST, SXT                  \-             \+              \-              \+              \+           \+
  30        Tracheal aspirate   AR      Nov. 2012   TIG, RIF                 Other     AK, TIG, CST, SXT                  \-             \+              \-              \+              \+           \+
  31        Tracheal aspirate   AR      Nov. 2012   TIG, SUL, CN, MEM, CST   Exitus    AK, TIG, CST, SXT                  \-             \+              \-              \+              \+           \+
  32        Tracheal aspirate   AR      Nov. 2012   NT                       Exitus    AK, TIG, CST, SXT                  \-             \+              \-              \+              \+           \+
  33        Blood               AR      Aug. 2012   CST, CSF, TIG            Other     AK, CN, CST                        \-             \+              \-              \+              \+           \+
  34        Wound               Uro     Jul. 2012   NT                       Other     AK, CN, TIG, CST                   \-             \+              \+              \+              \+           \+
  35        Sputum              AR      Nov. 2012   CST, SUL, TIG            Exitus    AK, TIG, CST, SXT                  \-             \+              \+              \+              \+           \+
  36        Blood               AR      Sep. 2012   CST, TIG                 Other     AK, TIG, CST                       \-             \+              \-              \+              \+           \+
  37        Tracheal aspirate   AR      Nov. 2012   NT                       Other     AK, TIG, CST, SXT                  \-             \+              \-              \+              \+           \+

Abbreviations: AR, anesthesiology and reanimation; Gas, gastroenterology; Neu, neurology; TS, thoracic surgery; RO, radiation oncology; CP, chest diseases polyclinic; IM, internal medicine; RICU, respiratory intensive care unit; PS, plastic surgery; Uro, urology; GS, general surgery; TZP, piperacillin/tazobactam; SCF, cefaperazone/sulbactam; AK, amikacin; CN, gentamicin; NET, netilmicin; TOB, tobramycin; CIP, ciprofloxacin; LEV, levofloxacin; TET, tetracycline; TIG, tigecycline; CST, colistin; SXT, trimethoprim/sulfamethoxazole; MEM, meropenem; SUL, sulbactam; RIF, rifampicin; CSF, cerebrospinal fluid; NT, Not treated; Other, the patient was transferred into a different service.
